Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development
FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo
Read a summary of this article on FAST.
Get bite-sized news via a new
cards interface. Give it a try.
Click here to return to FAST
Tap here to return to FAST
FAST
Oct 23 : Pathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer’s disease and other neurological disorders.
Pathos AI also raised $237 million in a Series E funding round led by Bristol Myers that valued the New York-based company at about $3 billion, with participation from existing investors.
Here are some other details:
• Tempus will build a dataset from hundreds of thousands of patients with neurological disorders to help track outcomes and speed research into disease biology
Guess Word
Crack the word, one row at a time
Buzzword
Create words using the given letters
Mini Sudoku
Tiny puzzle, mighty brain teaser
Mini Crossword
Small grid, big challenge
Word Search
Spot as many words as you can
• Pathos will license the data from Tempus under a five-year, $55 million agreement
• Pathos will apply its AI platform, Pathos Foundry, to study the dataset at scale, generate and test hypotheses on disease biology, and inform the design of more targeted, adaptive clinical trials
• Bristol Myers will gain non-exclusive strategic access to Pathos Foundry across its broader portfolio, as well as three-year exclusive rights to use the platform for its neuroscience development programs
• Proceeds from the financing will be used to further scale the Foundry platform’s capabilities and accelerate development of its AI-driven pipeline, including advancing experimental cancer drug, JSKN016
• The funding will help advance development of other cancer programs including an AstraZeneca-partnered experimental breast cancer drug
Source: Reuters
Sign up for our newsletters
Get the CNA app
Stay updated with notifications for breaking news and our best stories
Get WhatsApp alerts
Join our channel for the top reads for the day on your preferred chat app
Get bite-sized news via a new
cards interface. Give it a try.
Click here to return to FAST
Tap here to return to FAST
FAST
